Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Coherus Oncology, Inc.NASDAQ: CHRS
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was $53.59M, compared with -$264K a year earlier. Trailing-twelve-month financing cash flow was -$219.85M.
Context
- Financing cash flow amounted to 649.0% of revenue in FY2025, up 579.0 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $53.59M or moves back toward the trailing-twelve-month quarterly average of -$54.96M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (273.71M) USD
- Year-over-year change
- -46.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (273.71M) | -46.4% |
| FY2024 | 2024-12-31 | (186.97M) | -368.6% |
| FY2023 | 2023-12-31 | 69.6M | +28.1% |
| FY2022 | 2022-12-31 | 54.33M | +4.7% |
| FY2021 | 2021-12-31 | 51.88M | — |
Financing Cash Flow vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 financing cash flow of $219.85M is the largest of the 11 companies compared; the peer median is $55M.
- Its year-over-year change of +16.9% is the 7th highest of 11, against a peer median of +114.2%.
- Financing cash flow amounts to 468.9% of revenue for CHRS, versus a peer median of 311.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $219.85M | +16.9% | — | 468.9% | |
| LTM Mar 2026 | $215.52M | +89700.8% | +652.5% | 385.8% | |
| LTM Mar 2026 | $126.91M | +1085.3% | +379.4% | 364.0% | |
| LTM Sep 2026 | $117.69M | +118.3% | +53.0% | — | |
| LTM Mar 2026 | $89.31M | +520.7% | -5.8% | 258.5% | |
| LTM Mar 2026 | $82.13M | -42.0% | — | — | |
| LTM Mar 2026 | $27.87M | +110.1% | -36.8% | 96.4% | |
| LTM Mar 2026 | $26.83M | -17.0% | — | 34.4% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $24.21M | -50.6% | -7.8% | 1242.3% |
| LTM Mar 2026 | $15.99M | -76.2% | — | 27094.9% | |
| LTM Mar 2026 | $4.4M | +137.5% | +4.2% | 5.8% | |
| Peer median (excluding CHRS) | $55M | +114.2% | +4.2% | 311.2% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | 168.02M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| Deferred Income Tax | 9.44M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.36M | 50.74M | 43.11M | 27.8M | 16.97M |
| Change in Working Capital | 42.36M | (79.26M) | (36.83M) | 55.89M | (5.84M) |
| Accounts Receivables | 34.06M | 13.05M | (150.68M) | 149.35M | 93.56M |
| Inventory | (6.25M) | (47.35M) | (46.73M) | (31.95M) | (17.11M) |
| Accounts Payables | 874K | (4.55M) | 23.76M | (3.94M) | (19.56M) |
| Other Working Capital | 13.68M | (40.41M) | 136.83M | (57.57M) | (62.74M) |
| Other Non-Cash Items | 143.05M | 75.45M | 52.93M | (137.92M) | (321.59M) |
| Operating Cash Flow | (37.43M) | (241.12M) | (174.88M) | (20.44M) | (138.51M) |
| Capital Expenditures | (1.29M) | (2.04M) | (286K) | 0 | 0 |
| Acquisitions (Net) | 1.29M | 0 | 845K | 0 | 0 |
| Purchases of Investments | (182.49M) | (127.38M) | (19.51M) | 0 | (103.84M) |
| Sales of Investments | 181.36M | 0 | 157.64M | 14.89M | 21.46M |
| Other Investing Activities | (137.29M) | (37.43M) | 5.95M | 215.43M | 457.46M |
| Investing Cash Flow | (138.41M) | (166.85M) | 144.64M | 230.32M | 375.09M |
| Debt Repayment | (672K) | 49.93M | 0 | (223.41M) | (233.19M) |
| Common Stock Issued | 40.9M | 6.36M | 74.22M | 1.46M | 8.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54.3M | (1.96M) | (4.62M) | 34.98M | (48.77M) |
| Financing Cash Flow | 51.88M | 54.33M | 69.6M | (186.97M) | (273.71M) |
| Effect of Forex Changes | 0 | 0 | (12K) | 0 | 0 |
| Net Change in Cash | (123.96M) | (353.65M) | 39.34M | 22.91M | (37.13M) |
| Free Cash Flow | (38.72M) | (243.16M) | (175.17M) | (20.44M) | (138.51M) |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.